Evidence map›Paper›PMID 11007888›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2000

GluR3 autoantibodies destroy neural cells in a complement-dependent manner modulated by complement regulatory proteins.

K D Whitney, J O McNamara

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 98 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. The role of astrocytes in neuropathic pain.Frontiers in molecular neuroscience · 2022
    Review
  7. Review
  8. Review
  9. Antibodies Against the NHFrontiers in immunology · 2021
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Autoantibodies in Neuropsychiatric Disorders.Antibodies (Basel, Switzerland) · 2016
    Review
  15. Article
  16. Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy.Journal of neural transmission (Vienna, Austria : 1996) · 2014
    Review
  17. Article
  18. Brain-reactive antibodies and disease.Annual review of immunology · 2013
    Review
  19. Article
  20. Neuroprotective effects of reactive oxygen species mediated by BDNF-independent activation of TrkB.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2012
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

K D WhitneyEpilepsy Research Laboratory, Duke University Medical Center, Durham, North Carolina 27710, USA.
J O McNamara
Duke University · US

Funding

EPILEPSY, GLUTAMATE RECEPTORS AND RASMUSSENS SYNDROMER01NS036808 · NINDS · DUKE UNIVERSITY · PI MCNAMARA, JAMES O. · 1998 to 2005
$2.1M
NINDS NIH HHS NS 036808NINDS NIH HHS R01 NS036808
6 · The paper itself

Abstract

GluR3 autoantibodies have been implicated in the development of Rasmussen's encephalitis, a rare neurodegenerative disease of humans characterized by epilepsy and degeneration of a single cerebral hemisphere. GluR3 autoantibodies are found in some Rasmussen's encephalitis patients, and GluR3 antibodies raised in rabbits destroy cultured cortical cells in a complement-dependent manner. In this study, the cellular targets of anti-GluR3 antisera-mediated cytotoxicity were examined in mixed primary neuronal-glial cultures of rat cortex. Unexpectedly, astrocytes were the principal target of the cytotoxic effects as assessed by immunohistochemistry and lactate dehydrogenase activity; neurons were destroyed to a lesser extent. Astrocyte vulnerability was rescued by transfection with complement regulatory proteins, and neuronal resistance was defeated by impairing complement regulatory protein function. Astrocyte death may occur in Rasmussen's encephalitis, and destruction of this cell type may play a critical role in the progression of this disorder. The present findings suggest complement regulatory protein expression may in part determine the nature and severity of Rasmussen's encephalitis and other complement-dependent nervous system diseases and thus underscore the need for a systematic investigation of the expression of all known complement regulatory proteins in healthy and diseased nervous system tissues.

Indexed as

AnimalsAntibodies, MonoclonalAstrocytesAutoantibodiesCD59 AntigensCell DeathCells, CulturedCoculture TechniquesComplement Membrane Attack ComplexComplement System ProteinsCytoprotectionEncephalitisImmune SeraImmunohistochemistryL-Lactate DehydrogenaseNeuronsAntibodies, MonoclonalAutoantibodiesCD59 AntigensComplement Membrane Attack ComplexComplement System Proteinsglutamate receptor ionotropic, AMPA 3Immune SeraL-Lactate DehydrogenasePhosphatidylinositol Diacylglycerol-LyaseReceptors, AMPAType C Phospholipases

Identifiers

PMID11007888
PMCPMC6772766
OpenAlexW1930520388

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.